Close Menu

Natural Molecular Testing

As part of the settlement reached with the agency, NMT will also cease all operations, end its plans to reorganize, and liquidate its assets. 

GenMark Diagnostics CEO Hany Massarany elaborated recently on the company's plans for its automated NexGen system and its associated test menu, as well as GenMark's efforts to reach European customers.

Luminex hit a number of "unexpected speed bumps" in the third quarter that caused the company to miss both its internal and Wall Street's projections, and to lower its 2013 revenue guidance.

Natural Molecular Testing created a stir in the marketplace last week when it announced it would be converting its pharmacogenetic test services to a new panel based on Luminex's xMAP multiplex bead array technology.

NEW YORK (GenomeWeb News) – GenMark Diagnostics said after the close of the market Monday that it has lowered its annual revenue guidance to approximately $30 million from its previous expectation of $35 million.

NEW YORK (GenomeWeb News) – While GenMark Diagnostics continues to seek clarification around the consequences of Luminex's collaboration and licensing deal wit

The story has been updated to include comments from GenMark.

NEW YORK (GenomeWeb News) – Luminex and Natural Molecular Testing have entered into a multiyear collaboration and licensing deal, resulting in a comprehensive personalized medicine panel.

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.